Haemonetics Corporation (NYSE:HAE) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

Haemonetics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street rates Haemonetics “Moderate Buy”: Of 13 analysts, nine recommend buy, three hold, and one strong buy. The average 12-month price target is $130.50.
  • Quarterly results topped expectations: Haemonetics reported $1.35 per share in earnings versus $1.29 expected, while revenue of $357.76 million exceeded forecasts and rose 9.4% year over year.
  • Institutional investors reported several increased holdings, while a company accounting officer sold 836 shares at an average price of $120.99; insiders own 2.07% of the stock.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of Haemonetics Corporation (NYSE:HAE - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen brokerages that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $130.50.

A number of equities analysts have issued reports on HAE shares. Citizens Jmp increased their price target on Haemonetics from $115.00 to $144.00 and gave the stock a "market outperform" rating in a research report on Monday, November 16th. Wall Street Zen cut Haemonetics from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 7th. BTIG Research upped their target price on Haemonetics from $130.00 to $142.00 and gave the stock a "buy" rating in a research note on Thursday, November 5th. Jefferies Financial Group started coverage on Haemonetics in a research report on Friday, November 13th. They set a "buy" rating and a $150.00 target price on the stock. Finally, Mizuho set a $165.00 target price on Haemonetics in a research report on Thursday, November 5th.

Check Out Our Latest Analysis on Haemonetics

Insider Transactions at Haemonetics

In other news, CAO Farris Maryanne Maunsell sold 836 shares of Haemonetics stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $120.99, for a total value of $101,147.64. Following the sale, the chief accounting officer owned 5,828 shares in the company, valued at $705,129.72. This trade represents a 12.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.07% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its stake in shares of Haemonetics by 30.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,368,265 shares of the medical instruments supplier's stock valued at $144,078,000 after buying an additional 322,246 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Haemonetics by 21.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier's stock valued at $74,731,000 after buying an additional 233,119 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Haemonetics by 1,191.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier's stock valued at $47,762,000 after buying an additional 418,470 shares during the period. Bank of America Corp DE purchased a new stake in shares of Haemonetics during the 2nd quarter valued at approximately $33,326,000. Finally, London Co. of Virginia raised its position in shares of Haemonetics by 33.9% during the 1st quarter. London Co. of Virginia now owns 352,807 shares of the medical instruments supplier's stock valued at $19,884,000 after buying an additional 89,242 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Stock Performance

Shares of NYSE HAE opened at $120.13 on Friday. The company has a market capitalization of $5.47 billion, a PE ratio of 53.87, a price-to-earnings-growth ratio of 2.43 and a beta of 0.63. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.83 and a current ratio of 2.84. The company's fifty day moving average price is $115.20 and its 200 day moving average price is $82.75. Haemonetics has a 1 year low of $51.00 and a 1 year high of $132.00.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, beating analysts' consensus estimates of $1.29 by $0.06. The company had revenue of $357.76 million during the quarter, compared to analysts' expectations of $345.15 million. Haemonetics had a net margin of 7.52% and a return on equity of 27.42%. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.27 earnings per share. On average, research analysts predict that Haemonetics will post 5.32 earnings per share for the current year.

About Haemonetics

(Get Free Report)

Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals. The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.

See Also

Analyst Recommendations for Haemonetics (NYSE:HAE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Haemonetics Right Now?

Before you consider Haemonetics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.

While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines